Oxford Biomedica - Further deals anticipated in 2020
Oxford Biomedica’s (OXB) FY19 results highlight strong operational momentum despite capacity constraints. OXB is investing for future growth and...
39 Views
Oxford Biomedica - Juno deal expands CAR-T revenue streams
Following the 2017 commercial launch of partner Novartis’s Kymriah (a CD19-targeting CAR-T that is approved for pALL and DLBCL), Oxford Biomedica...
553 Views
Oxford Biomedica - OxBox investment to aid future growth
Oxford Biomedica (OXB) is a pioneer and global leader in the development and manufacture of commercial-scale lentiviral vectors (LVV), a critical...
679 Views
Oxford Biomedica - Novartis extends commercial supply agreement
Oxford Biomedica (OXB) has announced the expansion of its commercial supply agreement with Novartis by five years. While expected, this removes any...
1.6k Views
Oxford Biomedica - Investing for future growth
Oxford Biomedica’s (OXB) interim results highlight strong operational and financial momentum to date. The Novo Holdings equity investment (£53.5m)...
879 Views